Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer et al. · PI Boehringer Ingelheim

Primary endpoint

Time to the First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF)

Population

Heart Failure; n=3730

doi:10.1056/NEJMoa2022190

Historical

Current

Future

3 noemes

Historical

1 noeme

Published findings from this trial. Vote whether the expert body still believes each noeme stands given current evidence.

The EMPEROR-Reduced trial's stated primary conclusion — Empagliflozin reduces cardiovascular death or heart-failure hospitalization in HFrEF regardless of diabetes status. — replicates in independent cohorts.

cardiology

Current

1 noeme

Noemes tracking active replication, subgroup analysis, or long-term follow-up. Vote on the likelihood the original effect holds.

Recent follow-up analyses of EMPEROR-Reduced are confirming the original effect size in real-world data.

cardiology

Future

1 noeme

Open forecast horizons tied to this trial. Vote your probability that each resolves TRUE by the declared horizon.

By 2028, SGLT2 inhibitors will be prescribed for ≥70% of eligible HFrEF patients at guideline-adherent cardiology practices.

cardiology

71%

Semantically related trials

Nearest trials by noeme-centroid cosine distance. Lower = closer.

NCT03036124

0.1013

· 3 claims

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

NCT01035255

0.1123

· 3 claims

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

NCT01471522

0.1913

· 3 claims

Initial Invasive or Conservative Strategy for Stable Coronary Disease

NCT02062593

0.1986

· 3 claims

Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial

NCT01692379

0.2106

· 3 claims

Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke

NCT01804355

0.2181

· 3 claims

A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke